SynthesisBMC cancer2025
Prognostic and clinicopathological significance of tertiary lymphoid structure in esophageal squamous cell carcinoma: a systematic review and meta-analysis review.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tertiary lymphoid structures (TLS), ectopic immune cell aggregates in non-lymphoid tissues, have emerged as potential predictors of esophageal squamous cell carcinoma (ESCC) outcomes. Given increasing evidence, we conducted an updated meta-analysis to systematically evaluate their prognostic and clinicopathological significance. A comprehensive literature search was performed through PubMed, Embase, Web of Science, Scopus, and Cochrane Library (up to June 2024) for studies assessing TLS associations with TNM staging and survival outcomes (OS/PFS) in ESCC. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models. This meta-analysis incorporated seven studies comprising nine separate datasets that evaluated the impact of TLS in ESCC. The pooled analysis demonstrated a significant positive correlation between TLS presence and more advanced T stage (OR = 2.65, 95%CI: 1.86-3.78; p < 0.01) but not N stage (OR = 1.27, 95%CI: 0.85-1.89; p = 0.24). Additionally, TLS presence was significantly associated with enhanced overall survival (HR = 0.49, 95%CI: 0.41-0.58, p < 0.01) as well as progression-free survival (HR = 0.56, 95%CI: 0.45-0.69, p < 0.01). Notably, when assessed using combined HE and IHC criteria, the prognostic benefit of TLS was more pronounced, with HRs further decreasing to 0.40 (95% CI: 0.31-0.51) for OS and 0.50 (95% CI: 0.41-0.60) for PFS. These findings confirm that the presence of TLS, particularly when verified through combined HE staining and IHC, is an independent favorable prognostic factor in ESCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.